- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Vitality Biopharma Closes $1 Million Private Placement
Vitality Biopharma closed a $1 million private placement.
Vitality Biopharma (OTCQB:VBIO) closed a $1 million private placement.
As quoted in the press release:
As previously described on the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 27, 2017, on July 26, 2017, the Company entered into a securities purchase agreement in a private placement of an aggregate of 666,667 shares of the Company’s common stock and Warrants to purchase up to an aggregate of 333,334 shares of the Company’s common stock (the “Warrants”), at a price of $1.50 per Share (the “Offering”). Each Warrant is immediately exercisable, expires on the three year anniversary of the date of issuance, and has an exercise price of $2.00 per share.
Vitality Biopharma plans to use the proceeds from this financing for cannabinoid pharmaceutical research and development as well as for general corporate purposes. Company CEO Robert Brooke notes, “We are excited to obtain this additional investment from institutional investors, which is very helpful as we advance our proprietary cannabosides into clinical development.”
Click here to read the full press release.
Source: www.marketwired.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.